Skip to main content

Cullinan Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

CGEM$11.31+4.7%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Consolidated Balance Sheets

June 30, 2024December 31, 2023
Assets
Current assets:
Cash and cash equivalents$115,021$98,434
Short-term investments547,474368,633
Prepaid expenses and other current assets15,30413,124
Total current assets677,799480,191
Property and equipment, net836989
Operating lease right-of-use assets2,1212,543
Other assets460459
Total assets$681,216$484,182
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$1,555$2,493
Accrued expenses and other current liabilities20,70624,204
Operating lease liabilities, current1,2151,440
Total current liabilities23,47628,137
Long-term liabilities:
Operating lease liabilities, net of current portion1,5192,150
Total liabilities24,99530,287
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 647,500 shares issued and outstanding as of June 30, 2024 and December 31, 2023.——
Common stock, $0.0001 par value, 150,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 57,871,638 and 42,900,083 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively64
Additional paid-in capital936,724654,685
Accumulated other comprehensive loss(476)(129)
Accumulated deficit(280,033)(200,857)
Total Cullinan stockholders' equity656,221453,703
Noncontrolling interests—192
Total stockholders' equity656,221453,895
Total liabilities and stockholders' equity$681,216$484,182
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.